Clinical trial
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
NCT00401089 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Other · Completed
Key facts
| NCT number | NCT00401089 |
|---|---|
| Title | Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia |
| Official title | A Placebo-controlled Cross Study of Panax Ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients With Schizophrenia |
| Lead sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Other |
| Collaborators | Queen's University Northern Ontario School of Medicine Imperial College London |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia, Insulin Resistance, Obesity |
| Intervention type | Drug |
| Interventions | Panax Ginseng |
| Enrollment | 60 |
| Start date | Dec 1, 2002 |
| Primary completion | Dec 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Nov 17, 2006 |
| Last update posted | Dec 12, 2012 |
| Countries | Canada, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: